298288
Racial Disparity of the Impact of the Revised USPSTF Screening Mammography Recommendations
Methods: Women were recruited to a study of breast cancer risk factors from 2007 to 2013. This analysis included 11,982 women between 40 and 74 years of age without a history of breast cancer. Participants were asked if they had received a mammogram in the past 2 years. To determine the effects of the revised USPSTF guidelines, participants recruited from 2007-2010 were compared to those recruited from 2011-2013 with respect to recent mammographic use.
Results: One-fifth of the participants were African-American and 39% were 40-49 years of age. Among white women, a significant decrease in recent mammogram use from 2007-2010 to 2011-2013 of -11.31% was detected (P<0.001). Among African-American women, the change in recent mammogram use of -1.92% was not significantly different from zero (P=0.312). The difference between racial groups with respect to change in mammographic use was statistically significant (P<0.001).
Conclusion: A racial disparity was observed with respect to the change in mammographic use following the revised guidelines. Reasons for this disparity are under investigation.
Learning Areas:
Chronic disease management and preventionEpidemiology
Learning Objectives:
Describe the impact of the change in recommendations for screening mammography issued by the U.S. Preventive Services Task Force in 2009
Compare African-American and white women with respect to the change in mammographic use after the issuance of the revised recommendations
Keyword(s): Cancer Prevention and Screening, Cancer and Women’s Health
Qualified on the content I am responsible for because: I am the Director of Biostatistics for the Winthop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences and have analyzed the cross-sectional study that forms the basis of this abstract presentation.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.